Correct. I know quite a few big multi billion medical device companies that get in big trouble due to QA issues (product recalls, etc). Not just about sales/marketing/support, operations, finance, R&D, etc. So many facets to running a thriving yet sustainable multi billion corporation in pharma & medical device space.
Seagen could be a template to how the early partnership may be structured between NWBO & Merck. Hopefully, our end game would be positive with a massive buyout in an year or so (once we get FDA approvals and there is some data on combo trial?).